human cells
modified viral vector system
modified virus vector
animal cells
long-term immune surveillance of tumor cells
human pathogens
human counterparts
human virus vaccine vectors
long-term surveillance of tumors
Viral Vaccine Vectors
nuclei of infected cells
robust levels
life of uncertainty
aggressive bout of therapy
low levels of antigen
successful therapy
long-lasting immunity
cancer-free
unique product
cancer relapse
potential relapses
sustained immunity
blocking relapses
immune responses
depot of antigen
expensive therapies
Numerous therapies
novel class of versatile tumor vaccines
immediate-early genes
early stage of infection
exceedingly safe profile
Personalized Medicine Melanoma
lymphoma
deterrence of minimal residual disease
design
latency
tissue culture
rapid elimination
active neoplastic process
decades
millions of people
present iatrogenic concerns
important clinical need
patients
options
developers
time
approach
humans
host
replication
pipeline